BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
Ella Day | July 11, 2025 | News story | Research and Development | BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator in Paris-Saclay, France. The initiative, hosted within Servier’s research site and operated by BioLabs, will develop an AI-enabled platform for sterically-guided bispecific antibody design.
The XSeed Labs model, pioneered by BioMed X, brings together scientists from leading academic institutions and relocates them to pharma R&D environments. It aims to accelerate early-stage innovation by providing researchers with direct access to industrial infrastructure and mentorship.
The initial project, titled “New AI-Empowered Platform for Sterically Guided Design of Bispecific Antibodies”, will focus on improving the rational design of bispecific antibodies for oncology. These complex molecules are powerful cancer therapeutics but face challenges related to steric hindrance and target accessibility. By integrating machine learning, structural biology and immuno-oncology, the team intends to optimise antibody structures to enable more effective dual-target engagement.
BioMed X and Servier have issued an open call for project proposals from academic researchers worldwide. Selected scientists will join the new XSeed Labs team in Paris-Saclay, contributing to the growing global BioMed X innovation network.
This is BioMed X’s second XSeed Labs location, following its US launch with Boehringer Ingelheim in Connecticut, US, in 2024.
Ella Day
11/7/25
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
